新西兰 - 英文 - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - egg lecithin 1.2%{relative} (as a component in fish oil);  ; fish oil 10%{relative} (highly refined); glycerol 2.5%{relative} (as a component in fish oil) - emulsion for infusion - active: egg lecithin 1.2%{relative} (as a component in fish oil)   fish oil 10%{relative} (highly refined) glycerol 2.5%{relative} (as a component in fish oil) excipient: sodium hydroxide sodium oleate water for injection - for use as a fraction of the lipid emulsion component for total parenteral nutrition, providing supplements of long chain omega-3-fatty acids especially eicosapentanoic and docosahexanoic acid when oral or enteral nutrition is impossible, insufficient or contraindicated.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - fish oil 30 g; medium-chain triglycerides 60 g;  ; olive oil 50 g;  ; soya oil 60 g;   - emulsion for infusion - 20 % - active: fish oil 30 g medium-chain triglycerides 60 g   olive oil 50 g   soya oil 60 g   excipient: dl-alpha tocopherol egg lecithin glycerol sodium hydroxide sodium oleate water for injection - supply of energy and essential fatty acids to patients, as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contraindicated.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - olive oil, quantity: 50 g; fish oil - rich in omega-3 acids, quantity: 30 g; medium chain triglycerides, quantity: 60 g; soya oil, quantity: 60 g - injection, intravenous infusion - excipient ingredients: glycerol; sodium oleate; dl-alpha-tocopherol; water for injections; egg lecithin; sodium hydroxide - supply of energy and essential fatty acids to patients, as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contra-indicated.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - olive oil, quantity: 50 g; fish oil - rich in omega-3 acids, quantity: 30 g; medium chain triglycerides, quantity: 60 g; soya oil, quantity: 60 g - injection, intravenous infusion - excipient ingredients: glycerol; sodium oleate; dl-alpha-tocopherol; water for injections; egg lecithin; sodium hydroxide - supply of energy and essential fatty acids to patients, as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contra-indicated.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - olive oil, quantity: 50 g; fish oil - rich in omega-3 acids, quantity: 30 g; medium chain triglycerides, quantity: 60 g; soya oil, quantity: 60 g - injection, intravenous infusion - excipient ingredients: glycerol; sodium oleate; dl-alpha-tocopherol; water for injections; egg lecithin; sodium hydroxide - supply of energy and essential fatty acids to patients, as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contra-indicated.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - soya oil, quantity: 60 g/l; olive oil, quantity: 50 g/l; fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: water for injections; glycerol; dl-alpha-tocopherol; egg lecithin; sodium oleate; sodium hydroxide - parenteral nutrition for adult patients when oral or enteral nutrition is impossible, insufficient or contraindicated.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - olive oil, quantity: 50 g/l; fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: water for injections; dl-alpha-tocopherol; sodium oleate; sodium hydroxide; egg lecithin; glycerol - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - medium chain triglycerides, quantity: 60 g/l; fish oil - rich in omega-3 acids, quantity: 30 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; water for injections; sodium hydroxide; egg lecithin; glycerol; sodium oleate - parenteral nutrition for adult patients when oral or enteral nutrition is impossible, insufficient or contraindicated.

美国 - 英文 - NLM (National Library of Medicine)

alk-abello, inc. - egg yolk (unii: 4ips17b70t) (egg yolk - unii:4ips17b70t) - egg yolk 0.1 mg in 1 ml - these products are for diagnostic use only. diagnostic allergenic extracts are indicated for use in skin testing to establish the clinical relevance of specific allergens to which the patient has been exposed. by measuring skin test response the physician may assess the degree of sensitivity that patients have to the allergens. for extracts standardized in au and bau, see individual directions for use. allergenic extracts for diagnostic use only of coffee, mosquito, cottonseed, and flaxseed have not been shown by adequate data to be safe and effective for therapeutic use. patients on beta blockers can be non-responsive to beta agonists that may be required to reverse a systemic reaction (also, see boxed warning statement and adverse reactions ). the physician should carefully weigh the benefit derived from skin testing vs. the risk to the patient should a systemic reaction arise. patients with unstable asthma or steroid dependent asthmatics and patients with underlying cardiovascular disease are at greater r

美国 - 英文 - NLM (National Library of Medicine)

nelco laboratories, inc. - egg white (unii: 3e0i92z2gr) (egg white - unii:3e0i92z2gr) - egg white 0.05 g in 1 ml - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t